Settlement ensures care of 2,200 state prisoners with hepatitis C. Inmates will no longer be required to undergo drug or alcohol treatment as a precondition for care

Quick Read

A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain’s state-funded health service, the country’s healthcare cost agency NICE said on Tuesday

Quick Read

In this town, carved into the Appalachian mountains, in a state beset by hepatitis C rates seven times the national average, Harvoni and other new hepatitis C drugs remain largely out of reach. Over the past year, only 3 percent of the state’s Medicaid beneficiaries with the disease received treatment

Quick Read

Request for life-saving anti-viral medication rejected on technicality. Judge finds Pennsylvania protocol for inmates out of line with constitution

Quick Read

Two Washington state insurers — Group Health Cooperative and BridgeSpan — are targeted in class-action lawsuits that claim the companies are unfairly rationing new drugs that can cure hepatitis C based on high cost, not medical need

Quick Read

Public anger at drug companies is “an abomination,” Ron Cohen, chairman of the big industry group BIO, said at the Biotech Showcase. All the talk about pharma profiteering, Cohen said, is “a perversion of reality.”

Quick Read

All told, 33 states spent more than $1 billion to treat the disease with Gilead Sciences’ Sovaldi, according to data released Tuesday by Sens. Charles Grassley, R-Iowa, and Ron Wyden, D-Ore.

Quick Read

Treating Hep C isn’t cheap, but experts say it’s cost-effective

Quick Read